Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04360824 · ClinicalTrials.gov registry record · Phase 4
Covid-19 Associated Coagulopathy
A Phase 4 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 4
- Development phase
- 176
- Enrollment target
NCT04360824 is a Phase 4 study that has completed, run by University of Iowa. The registered enrollment target is 176 participants.
The verdict
NCT04360824, a Phase 4 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 176 participants
- Enrollment target
Study Summary
This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who meet the modified ISTH Overt DIC criteria score ≥3. Patients will be randomized to standard prophylactic dose LMWH (standard of care arm) or intermediate-dose LMWH (intervention arm).
Interventions
- DRUG Intermediate dose thromboprophylaxis
- DRUG Standard of Care thromboprophylaxis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2020-05-06 |
| Est. Completion | 2021-04-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04360824
The ClinicalTrials.gov registry entry for NCT04360824 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intermediate dose thromboprophylaxis is the first listed.
NCT04360824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04360824 about?
NCT04360824 is a clinical study titled "Covid-19 Associated Coagulopathy". This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who meet the modified ISTH Overt DIC criteria score ≥3. Patients will be rand...
What is the current status of trial NCT04360824?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 176 participants. The study started on 2020-05-06. Estimated completion is 2021-04-16.
What interventions are being tested in trial NCT04360824?
The interventions under investigation include: Intermediate dose thromboprophylaxis (DRUG), Standard of Care thromboprophylaxis (DRUG).
Who is sponsoring clinical trial NCT04360824?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.